论文部分内容阅读
目的 评价肝动脉化疗栓塞（ＴＡＣＥ） 及Ｂ 超引导下注射３２Ｐ胶体、无水乙醇（ＰＥＩ） 综合序贯介入治疗原发性肝癌的临床价值。方法 ５１ 例中晚期肝癌分为２ 组，２３ 例综合序贯应用ＴＡＣＥ＋ ３２Ｐ＋ ＰＥＩ治疗，２８ 例单纯应用ＴＡＣＥ 治疗。结果 综合序贯组肿瘤缩小率、肿瘤完全坏死率、ＡＦＰ下降率分别为９１ ．２９ ％ 、８０ ．００ ％ 、８７ ．５ ％ ，而单纯ＴＡＣＥ组分别为３９．２７％ 、３０ ．４３％ 、４１ ．４６ ％ ，两组比较有显著性差异（ Ｐ＜０ ．０１），６ 个月、１、２ 、３ 年生存率综合序贯组分别为９５．６５ ％ 、８６．９５％ 、５６ ．５２ ％ 、２０．７３ ％ ，而单纯ＴＡＣＥ 组分别为６４．２８％ 、３９．２８ ％ 、１７ ．８５ ％ 、００ ．００ ％ （Ｐ＜ ０．０１） 。结论 ＴＡＣＥ＋ ３２Ｐ＋ ＰＥＩ的综合序贯介入治疗是提高中晚期原发性肝癌患者生存率的有效方法。
Objective To evaluate the clinical value of transcatheter hepatic arterial chemoembolization (TACE) and B-guided injection of 32P colloid and absolute ethanol (PEI) in sequential treatment of primary liver cancer. Methods Totally 51 cases of advanced hepatocellular carcinoma were divided into two groups. TACE + 32P + PEI was used in 23 cases and TACE was used in 28 cases. Results The rate of tumor shrinkage, complete tumor necrosis and AFP reduction in sequential group were 91% and 91%, respectively. 29%, 80. 00%, 87. 5%, while the simple TACE group was 39.27%, 30 respectively. 43%, 41. 46%. There was significant difference between the two groups (P <0.01). The 6-month, 1-, 3-, and 3-year survival rates were 95.65%, 86.95%, 56 respectively. 52% and 20.73% respectively, while those in pure TACE group were 64.28% and 39.28% respectively. 85%, 00. 00% (P <0.01). Conclusion TACE + 32P + PEI combined sequential intervention is an effective way to improve the survival rate of patients with primary liver cancer in the late stage.